Kornimate/medical-research-clean huggingface dataset:
comparison of two therapies for upper esophageal sphincter (ues) dysphagia

Conditions: Deglutition Disorders

Summary: the aim of this research study is to determine the effectiveness of: 1) a traditional therapy regimen focusing on individual exercises for pharyngeal (throat) and laryngeal (voice box) musculature and 2) a new therapeutic exercise, the shaker exercise. the primary objective of this 5-year project is to identify which of two therapy programs, the shaker exercise versus traditional therapy, results in the largest number of stable, non-oral dysphagic patients who can swallow safely and return to full oral feeding after 6 weeks of intervention. the study is powered adequately so that this aim can be tested separately for head and neck cancer and stroke patients. our primary outcome measure is return to oral feeding, i.e., 100% of nutrition and hydration by mouth.

secondary aims of this research are: 1. determine in a descriptive manner whether patients with residue in the pyriform sinuses who aspirate the residue after the swallow respond better, i.e., a higher percentage of them can return to 100% oral intake, than patients with residue in the valleculae who aspirate after the swallow or patients with residue in both locations who aspirate after the swallow and thus to define the spectrum of indications for the proposed exercise programs in the two groups of dysphagic patients (stroke and post-chemo radiation treatment for head and neck cancer) and whether postures enable each patient type to swallow more bolus types without aspiration at pre- and post 2. define the pathophysiology underlying the swallow dysfunction and those pathophysiologic elements which change as a result of each therapy program including changes in - 1. anteroposterior and lateral diameter of maximum deglutitive ues opening 2. maximum deglutitive laryngeal anterior and superior excursions

Eligibility criteria:
inclusion criteria (all required) * patients with pharyngeal phase dysphagia due to stroke or chemoradiation for head and neck cancer (without surgical intervention) * incomplete ues opening and post-deglutitive aspiration * hypopharyngeal (pyriform sinus) residue or vallecular residue alone or in combination * dysphagia requiring tube feeding (at least 3 months non-oral condition) * able to comply with protocol mandates, willing to perform the exercise programs, and ability to attend study sessions. exclusion criteria * pharyngeal surgical procedures * other neuromuscular disorders such as * lack of cognition * metabolic myopathies * history of alcoholic neuropathy * steroid myopathy * cervical spine injury, lesions, or large osteophytes * kerns-sayers syndrome * individuals unable to exercise independently * oculo-pharyngeal and other dystrophies * current use of anticholinergics: bensodiazopin, antihistamines * myasthenia gravis * elimination of aspiration with posture during vfg * absent pharyngeal swallow on vfg * aspiration before or during the swallow (pre and intradeglutitive aspiration) * not completely tube feeding dependent

Keywords: ues dysphagia
comparison of sequential therapies with sunitinib and sorafenib in advanced renal cell carcinoma

Conditions: Metastatic Renal Cell Carcinoma

Summary: the clinical benefits of sunitinib and sorafenib have been demonstrated in patients with cytokine-refractory metastatic renal cell carcinoma. sunitinib has also been shown to improve progression free survival and overall survival in a comparative study with interferon-alpha. when sunitinib is used as first-line molecular-targeted therapy, switching to sorafenib is one of the treatment options after disease progression. reversely, when sorafenib is used as first-line molecular-targeted therapy, sunitinib is used as second-line therapy. the goal of cancer treatment is cure, and if cure is not possible, it is to prolong survival. in this study, sunitinib or sorafenib will be administered as first-line molecular-targeted therapy and treatment switched to the other test drug, sorafenib or sunitinib, when disease progression is detected to assess which treatment sequence produces longer progression free survival and offers a better safety profile (causing fewer adverse events). the purpose of this trial is to compare progression free survival of first line sunitinib versus sorafenib, and that of two treatment sequences, i.e. sunitinib followed by sorafenib versus sorafenib followed by sunitinib.


Eligibility criteria:
inclusion criteria: * age: 20-80 years old, both inclusive * ecog performance status of 0, 1, or 2 * mskcc risk of favorable or intermediate * histologically confirmed renal cell carcinoma * no ischemic heart disease * laboratory findings meet the following criteria: 1. respiratory function: %vc, 80% and fev1.0,70% 2. hematology: white blood cell count4,000/mm3, platelet count100,000/mm3 3. clinical chemistry: got and gpt within the normal range of each medical institution; total bilirubin \<1.5 x uln 4. serum creatinin \<2.0mg/dl, blood urea nitrogen (bun) \<25mg/dl 5. echocardiographic estimation of left ventricular ejection fraction is higher than the lower limit of reference range of each medical institution. exclusion criteria: * history of any other malignancy * central nervous system metastases. however, patients who remain asymptomatic, have no new or enlarging lesion in the cns within 6 months of enrollment in this study, and require no corticosteroids may be enrolled. * history of cardiac infarction, unstable angina, congestive heart failure, or symptomatic peripheral vascular disease within 12 months of enrollment * history of cerebrovascular disorder including transient ischemic attack (tia) * pregnancy or possible pregnancy at any time during the study * ongoing grade 2 adverse event prior treatment * prior treatment with any anticancer therapy including cytokine therapy such as interferon-alpha and interleukin-2 * prior treatment with mtor inhibitor * prior treatment with sunitinib or sorafenib * treatment with an test drug in a clinical research within 4 weeks of enrollment in this study

Keywords: renal cell carcinoma sorafenib sunitinib crossover
study to evaluate the reliability, validity and safety of subjective mobile refraction

Conditions: Refractive Errors

Summary: this study evaluates the reliability, validity and safety of a self administered, subjective refraction test via a mobile medical app (goeyes) as compared to standard of care subjective manifest refraction performed by a health care provider, in subjects who have no known ocular disease or condition other than refractive error.

goeyes is a mobile medical application, which can be downloaded to a smartphone and is being developed as a self -administered subjective refraction examination that measures the refractive error of the user's eyes in the home environment without any contact or help from health care professionals. the study will be conducted in 2 parts; part 1 and part 2. approximately 59 participants will be enrolled in part 1. part 1 participants will have a goeyes refraction test in clinic on two separate days and will also have a standard of care refraction test performed by a health care provider and best corrected visual acuity assessments. approximately 349 participants will be enrolled in part 2. part 2 participants will self administer the goeyes test at home on 2 separate days and will also have in clinic standard of care refraction test performed by a health care provider and best corrected visual acuity assessments.

Eligibility criteria:
inclusion criteria: 1. males or females aged 18-39 years who currently wear glasses and/or soft contact lenses to correct refractive error 2. normal color vision 3. able to use both hands at the same time and to hear, understand and verbally respond to audio instructions 4. have single vision lenses only 5. able to provide informed consent - exclusion criteria: 1. have any ongoing disease or ocular condition other than refractive error 2. have a history of permanent vison loss 3. have a neurological condition affecting vision 4. have worn glasses since age 6 or younger 5. have a prism in their prescription 6. use rigid gas permeable lenses or orthok lenses 7. have had laser refractive surgery or any other eye surgery 8. use prescription eye drops -

Keywords: refractive errors myopia mobile applications
liquid biopsy in advanced oligometastatic nsclc receiving surgery

Conditions: Non-small Cell Lung Cancer; Oligometastatic Disease

Summary: a prospective, observational study that assesses the clinical feasibility of ctdna-based liquid biopsy in patients with oligometastatic nsclc receiving surgery.

60 eligible patients will be enrolled. dynamic blood samples before and after surgery and tissue samples will be obtained for exploratory analysis.

Eligibility criteria:
inclusion criteria: * written informed consent must be obtained from patients and ability for patients to comply with the requirements of the study； * patients must be a man or woman of more than 18 years; * ecog ps ≦1； * the function of the organs was evaluated by the surgeon to tolerate local surgical treatment； * the classification was evaluated as simultaneous oligometastases at initial treatment or oligoresidual/oligoprogression/oligorecurrence after induction therapy; \[define: initial treatment of simultaneous oligometastases: without systemic treatment, at the time of diagnosis, up to 5 metastases and up to 3 organs were involved, excluding pleural metastases or myeloid metastases. oligoresidual after induction therapy: after systemic therapy, distant metastases were stable or reduced, primary lesions were stable or reduced, pet/ct metabolism was reduced, and no more than 5 residual lesions and no more than 3 organs were involved. oligoprogression after induction therapy: after systemic therapy, some lesions were stable or reduced, while some original lesions were larger than before. oligorelapses after induction therapy: after systemic therapy, systemic lesions were stable or reduced, and new local lesions appeared.\] * lesion evaluation can be surgically removed. \[definition of operable resection: the lesion is limited and can be completely removed through surgery as assessed by the surgeon, with no significant impact on postoperative quality of life. pulmonary surgical procedures include lobectomy, segmental resection and wedge resection. pneumonectomy is not included.\] exclusion criteria: * patients with a confirmed or suspected autoimmune disease; * patients with a history of human immunodeficiency virus (hiv) positive or acquired immunodeficiency syndrome (aids); * patients with a history of any arterial thrombosis within 6 months and history of deep vein thrombosis, pulmonary embolism, or any other severe thromboembolism within 3 months; * patients with any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.); * patients with a history of other malignancies in the past 5 years; * patients identified by the investigators patients with contraindications to local treatment; * patients with serious mental illness; * patients who cannot sign informed consent; * patients who cannot be followed up as scheduled;
the safety and effectiveness of different doses of vitamin c in hiv-infected patients

Conditions: HIV Infections

Summary: this is a study to evaluate the tolerance and antiviral effect of oral vitamin c in hiv-infected.


Eligibility criteria:
not applicable - study withdrawn since 04/23/1996
biomarkers for the activity of immune checkpoint inhibitor therapy in patients with advanced melanoma

Conditions: Malignant Melanoma

Summary: 1. screen and recruitment: patients will be screened based on their prior history and intention to initiate treatment with an immune checkpoint inhibitor. 2. study phase: * collection of baseline demographic data, prior disease history, nature of ici therapy, outcome data of ici therapy (treatment disposition, toxicity, tumor response and survival). * collection of blood samples will be performed every 3 to 4 weeks for the first year on ici therapy and every 6 to 12 weeks thereafter until the end of ici therapy, disease progression, death or loss to follow-up. collection of blood samples will be aligned with the visits necessary for the administration of the ici therapy. * collection of archival melanoma metastasis tissues will be performed on a continuous basis and be triggered by availability of such tissue following therapeutic resections of melanoma metastases. 3. follow-up phase

1. screen and recruitment: patients will be screened based on their prior history and intention to initiate treatment with an immune checkpoint inhibitor. this screening of candidate patients by the investigators will be non-interventional. patients that are considered eligible candidates will be invited to participate in this study and to page 3/18 provide written informed consent. 2. study phase: * collection of baseline demographic data, prior disease history, nature of ici therapy, outcome data of ici therapy (treatment disposition, toxicity, tumor response and survival). * collection of blood samples will be performed every 3 to 4 weeks for the first year on ici therapy and every 6 to 12 weeks thereafter until the end of ici therapy, disease progression, death or loss to follow-up. collection of blood samples will be aligned with the visits necessary for the administration of the ici therapy. * collection of archival melanoma metastasis tissues will be performed on a continuous basis and be triggered by availability of such tissue following therapeutic resections of melanoma metastases. 3. follow-up phase: patients who stop treatment with the immune checkpoint inhibitor will be followed-up for

Eligibility criteria:
inclusion criteria: 1. histologically confirmed malignant melanoma; 2. ajcc stage iiic or iv melanoma with evaluable disease; 3. treatment with an immune checkpoint inhibitor; 4. willing and able to give written informed consent; 5. accessible for treatment and follow-up; exclusion criteria: * non

Keywords: melanoma
efficacy of nutritional supplement viusid/alzer in patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of the study is to evaluate whether viusid/alzer nutritional supplements, could improve the progression disease, in patients with parkinson's disease (pd).

periodical measures of the clinical features with updrs will be done at the beginning, each three months until two years. each group will be compare to evaluate.

Eligibility criteria:
inclusion criteria: * patients with clinical of pd, with the criteria of brain bank of london with early stage. * informed consent. exclusion criteria: * presence of another disease not well controlled. * patient with atypical features. * patient with advanced parkinson's disease.
use of mobile teledermatology in the care of acne patients

Conditions: Acne

Summary: the purpose of the present study is to determine whether a mobile teledermatology care model can achieve better clinical outcomes as compared to conventional, outpatient care for the management of severe acne treated with isotretinoin. the superiority of mobile care in comparison to conventional, outpatient care will be investigated regarding 1. effectiveness: global evaluation acne (gea) score -response at week 24 2. safety: drop out rates and medication side effects 3. overall patient satisfaction with acne care and therapy 4. overall physician satisfaction with mobile acne care


Eligibility criteria:
inclusion criteria: female or male, aged 12 to 30 years * with facial acne * requiring systemic isotretinoin treatment (gea-score: 3-5) * with basic handy skills * with a signed consent form exclusion criteria: * pregnancy or lactation period * withdrawal of informed consent * non-compliance, failure to comply with protocol requirements

Keywords: mobile teledermatology telemedicine acne
commd7 gene expression in all

Conditions: ALL

Summary: * study the expression pattern of commd7 gene in acute lymphoblastic leukemia. * investigate correlation between the expression level of commd7 gene with other diagnostic parameters and prognosis in all .

acute lymphoblastic leukemia (all) is a neoplastic disorder of lymphoid progenitor cells characterized by diverse cytogenetic and molecular abnormalities with peaks of prevalence for 2-5-year-old patients and those older than 50. treatment strategies using risk-adapted chemotherapy cure more than 80% of childhood cases, but around 20 to 30% relapse developing serious complications including death.( 1) in the past decade, the available treatments for patients with acute lymphoblastic leukemia (all) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes.(2) the copper metabolism murr1 domain (commd) protein family involved in tumor development and progression in several types of human cancer, but little is known about the function of commd proteins in hematological malignancy. (3) commd7, a member of the commd, which is located on chromosome 20q11.21, has been reported associated with tumor progression in human solid cancers \[4\]. commd7 is overexpressed in pancreatic ductal adenocarcinoma (pdac) cells, associated with poor prognosis. \[5\]. another study revealed that commd7-overexpressed hepatocellular carcinoma (hcc) cells promoted the proliferation of naïve hcc cells (6) a recent study was found that high expression of commd7 is a potential biomarker for adverse outcomes and poor prognosis in aml. (7) . however, to date, the expression of commd7 in acute lymphoblastic leukemia and its prognostic value remain unclear.

Eligibility criteria:
inclusion criteria: * patients newly diagnosed with acute lymphoblastic leukemia , male or female at any age. exclusion criteria: * history of anti-neoplastic therapy, such as chemotherapy or radiotherapy. * any other types of cancers. * any clinically systemic acute or chronic inflammatory disease/s within one months.

Keywords: commd7 , all
allopurinol to prevent cirrhosis related morbidities

Conditions: Cirrhosis

Summary: the study aims to compare the potential benefit of allopurinol in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. furthermore, the study aims to evaluate their impact on parents' related quality of life

cirrhosis is the late stage of liver damage and possess two phases: a compensated phase with favorable prognosis and a decompensated phase with high mortality rate.the shift from compensated to decompensated cirrhosis is characterized by the onset of complications, including ascites, hepatic encephalopathy (he), variceal bleeding, and spontaneous bacterial peritonitis (sbp) which are associated with substantial morbidity and negative impact on quality of life (qol). the gut microbiota plays an important role in cirrhosis and development of cirrhosis-related complications. indeed, translocation of endotoxins is increased in patients with cirrhosis and patients with more severe cirrhosis (i.e. patients with decompensated cirrhosis, hospitalized patients) had significantly greater serum endotoxin concentrations that mediate complications of cirrhosis. intestinal permeability plays a role in the development of bacterial translocation and may be involved in the development of complications of cirrhosis. this 'leaky gut' phenomenon increases with the degree of liver failure and is particularly prominent in patients with cirrhosis who have experienced severe septic complications and has been implicated in the hepatic production of endotoxin-associated proinflammatory cytokines. intestinal mucosa alterations at the subcellular level have been reported in experimental cirrhosis, in relation to an increased oxidative stress due to overactivity in the enzyme xanthine oxidase. allopurinol, a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation in portal hypertensive animals, suggesting that the damaging effects of oxygen-derived free radicals and peroxidation on mucosal cells may be counteracted by a free radical scavenger. in 2007, a pilot study demonstrated that allopurinol in patients with cirrhosis is associated with a significant reduction in oxidative stress but no effect on intestinal permeability and inflammatory markers. the study duration was only 10 days and therefore another study with a long period of time is essential.

Eligibility criteria:
inclusion criteria: * ge 18 to 75 years old both sex adults with cirrhosis in a stable conditions exclusion criteria: * active sbp renal insufficiency (serum creatinine \> 2.0 mg/dl) active git hemorrhage
autonomic and enteric profiling

Conditions: Gastroparesis

Summary: autonomic, inflammatory, enteric, electrophysiologic and hormonal.

patients were evaluated by two methods in each of five areas: inflammatory, autonomic, enteric, electrophysiologic, and hormonal. in part one, patients had similar gi symptoms regardless of baseline gastric emptying or diabetic/non-diabetic status and all patients demonstrated abnormalities in each of the 5 areas studied. in part two, patients showed early and late effects of electrical stimulation with changes noted in multiple areas, categorized by improvement status.

Eligibility criteria:
inclusion criteria: 1. willingness to participate in study and sign informed consent. 2. age 18 or older. 3. symptoms of gastroparesis for at least 6 months. 4. refractory or intolerant to antiemetic drugs. 5. refractory or intolerant to prokinetic drugs. 6. if diabetic, documentation of medication for diabetes for at least 6 months. 7. no evidence of anatomic obstruction of gi tract. - exclusion criteria: 1. previous gastric surgery. 2. history or evidence of rumination syndrome, eating disorder of primary psychiatric disorder. 3. no know collagen vascular disease. 4. inability or unwillingness to participate in the study. 5. current active gastric stimulation or other gastrointestinal neurostimulation implant or device. 6. pregnancy.

Keywords: gastroparesis nausea and vomiting abdominal pain gastric emptying electrophysiology hormones inflammation enteric nervous system autonomic nervous system